Cannara Biotech (8CB0) Price & Analysis

0 Followers

8CB0 Stock Chart & Stats

€1.11

-€0.03(-2.63%)

At close: Jul 28 4:00 PM EDT

€1.11

-€0.03(-2.63%)

Day’s Range― - ―

52-Week Range€0.83 - €1.24

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€113.54M

Enterprise Value€183.06

Total Cash (Recent Filing)€21.81M

Total Debt (Recent Filing)€37.00M

Price to Earnings (P/E)17.2

Beta0.28

Next Earnings

Nov 24, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.11

Shares Outstanding98,782,150

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.64

Price to Sales (P/S)1.57

P/FCF Ratio12.31

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€2.07

Price Target Upside86.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)0.07

Revenue Forecast (FY)€75.87M

Bulls Say, Bears Say

Bulls Say

Revenue Scaling & Profitability TurnaroundSustained multi-year revenue growth and return to net profitability reflect durable demand and successful market execution. Higher scale supports fixed-cost absorption, funds reinvestment in capacity and brands, and improves resilience to cyclical dips, strengthening long-term earnings power.

Consistent Cash ProfitabilityA long streak of positive adjusted EBITDA and operating cash flow indicates repeatable operating cash generation. Reliable cash conversion underpins internal funding for expansion, lowers dependency on external financing and provides flexibility to weather industry cycles over the medium term.

Accelerated Capacity Build & Strategic PartnershipsFaster capacity expansion plus targeted M&A and tech exclusives create durable supply-side advantages and route-to-market scale. The Curaleaf supply pact and acquired IP expand addressable markets and product capabilities, supporting sustainable revenue growth and competitive positioning over years.

Bears Say

Margin Compression And Earnings VolatilitySignificant margin decline and swing in operating income indicate vulnerability to product-mix shifts and cost pressures. Persistently lower margins would reduce cash available for capex and debt servicing, make earnings more sensitive to volume fluctuations, and could weaken leverage metrics if sustained.

Free Cash Flow Volatility & Working-capital BuildSharp decline in FCF and a material build in receivables and inventory tie up liquidity and raise financing risk during expansion. If sales or margins underperform, higher working capital could force incremental borrowing or slow investments, stressing balance-sheet flexibility in the medium term.

Competitive Shelf Pressure & International Timing RiskIntensifying retail competition pressures pricing, SKU placement and marketing spend, reducing margin upside. Meanwhile, the multi‑year uncertainty around EU GMP delays meaningful international revenue from Curaleaf sponsorship, slowing diversification and delaying returns on expansion investments.

Cannara Biotech News

Cannara Biotech price target raised to C$4 from C$3.25 at TD Securities

TD Securities raised the firm’s price target on Cannara Biotech (LOVFF) to C$4 from C$3.25 and keeps a...

19d ago

Source Rock Royalties Declares Monthly Dividend and Grants RSUs to Leadership

The latest update is out from Cannara Biotech ( ($TSE:LOVE) ). Source Rock Royalties has declared a monthly...

19d ago

Cannara Biotech: Buy Rating Reiterated on Strong Q3 Beat, Operational Expansion, and $3.00 Price Target

Atrium Research analyst Nicholas Cortellucci has maintained their bullish stance on LOVFF stock, giving a Buy rating on...

20d ago

Cannara Biotech Earnings Call Highlights Growth and Expansion

Cannara Biotech, Inc. (($TSE:LOVE)) has held its Q3 earnings call. Read on for the main highlights of the...

20d ago

LOVFF Upcoming Earnings Report: What to Expect?

Cannara Biotech, Inc. (LOVFF) is scheduled to report 3rd quarter earnings on 07/15/2026, before the market opens. Regarding...

22d ago

Cannara Biotech Posts Solid Q2, Becomes Top Cannabis Retailer in Québec

Cannara Biotech ( ($TSE:LOVE) ) just unveiled an update. Cannara Biotech reported Q2 fiscal 2026 results showing continued...

4M ago

Cannara Biotech Sets Date for Q2 2026 Results as Haywood Securities Initiates Coverage

Cannara Biotech ( ($TSE:LOVE) ) just unveiled an update. Cannara Biotech Inc., a Québec-based vertically integrated cannabis producer,...

4M ago

Cannara Biotech Wins TSX Listing and TD Cowen Coverage

Cannara Biotech ( ($TSE:LOVE) ) has shared an update. Cannara Biotech has secured final approval to graduate from...

5M ago

Cannara Biotech to Uplist Shares to Toronto Stock Exchange

The latest announcement is out from Cannara Biotech ( ($TSE:LOVE) ). Cannara Biotech has secured final approval to...

5M ago

Cannara Biotech graduates to TSX

Cannara Biotech (LOVFF) received final approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange....

5M ago

Cannara Biotech initiated with a Buy at TD Securities

TD Securities analyst Derek Lessard initiated coverage of Cannara Biotech (LOVFF) with a Buy rating and C$3.25 price...

5M ago

Cannara Biotech Schedules Investor Webcast to Highlight Cannabis Operations

Cannara Biotech ( ($TSE:LOVE) ) has provided an announcement. Cannara Biotech Inc., a vertically integrated Canadian cannabis producer...

6M ago

Cannara Biotech Secures C$6.3 Million Premium Private Placement from Phoenician Capital

The latest announcement is out from Cannara Biotech ( ($TSE:LOVE) ). Cannara Biotech has completed a strategic C$6.3...

6M ago

Cannara Biotech prices 3M shares at C$2.10 in private placement

Cannara Biotech (LOVFF) completed a strategic, non-brokered private placement with Phoenician Capital. Pursuant to the terms of a...

6M ago

8CB0 FAQ

What was Cannara Biotech’s price range in the past 12 months?

Cannara Biotech lowest stock price was €0.83 and its highest was €1.24 in the past 12 months.

What is Cannara Biotech’s market cap?

Cannara Biotech’s market cap is €113.54M.

When is Cannara Biotech’s upcoming earnings report date?

Cannara Biotech’s upcoming earnings report date is Nov 24, 2026 which is in 112 days.

How were Cannara Biotech’s earnings last quarter?

Cannara Biotech released its earnings results on Jul 15, 2026. The company reported €0.031 earnings per share for the quarter, the consensus estimate of €0.031 by €0.

Is Cannara Biotech overvalued?

According to Wall Street analysts Cannara Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cannara Biotech pay dividends?

Cannara Biotech does not currently pay dividends.

What is Cannara Biotech’s EPS estimate?

Cannara Biotech’s EPS estimate is 0.02.

How many shares outstanding does Cannara Biotech have?

Cannara Biotech has 98,782,150 shares outstanding.

What happened to Cannara Biotech’s price movement after its last earnings report?

Cannara Biotech reported an EPS of €0.031 in its last earnings report, expectations of €0.031. Following the earnings report the stock price went up 6.604%.

Which hedge fund is a major shareholder of Cannara Biotech?

Currently, no hedge funds are holding shares in DE:8CB0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cannara Biotech

Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.

Cannara Biotech (8CB0) Earnings & Revenues

Historic Earnings Reports

8CB0 Company Deck

8CB0 Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presents a broadly positive operational and financial picture: double-digit revenue growth (16% QoQ), continued profitability (adjusted EBITDA up 11% and 21 consecutive positive quarters), strengthened market penetration (national share gains and record monthly shares in Ontario and Alberta), accelerated capacity expansion and strategic partnerships (Medican acquisition, Blue River technology, CAD 21M Curaleaf agreement). Notable near-term negatives include lower quarterly free cash flow and operating cash flow versus the prior year driven by higher expansion capex, a modest dip in gross margin from product mix, higher receivables and inventory, and competitive pressures in certain categories. On balance, the highlights — consistent profitability, expanding distribution and market share, accelerated capacity rollout, and strategic deals — outweigh the lowlights tied to timing, investment-driven cash flow effects, and category competition.View all DE:8CB0 earnings summaries

8CB0 Stock 12 Month Forecast

Average Price Target

€2.07

▲(86.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.47903512,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.0658626,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.85927634,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.215310393846154,1.3206207876923077,1.4259311815384617,1.5312415753846154,1.6365519692307693,1.741862363076923,1.847172756923077,1.9524831507692308,2.0577935446153846,2.1631039384615383,2.2684143323076924,2.373724726153846,{"y":2.47903512,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.1835278923076924,1.2570557846153847,1.330583676923077,1.4041115692307693,1.4776394615384616,1.551167353846154,1.6246952461538462,1.6982231384615385,1.7717510307692308,1.845278923076923,1.9188068153846154,1.9923347076923077,{"y":2.0658626,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.1676366415384616,1.225273283076923,1.2829099246153848,1.3405465661538463,1.3981832076923078,1.4558198492307692,1.5134564907692307,1.5710931323076924,1.628729773846154,1.6863664153846154,1.744003056923077,1.8016396984615386,{"y":1.85927634,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.06,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.975,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >